Search Videos by Topic or Participant
Browse by Series:

Lenvatinib in Metastatic Renal Cell Carcinoma

Insights From: Prof. Bernard Escudier, MD, Institute Gustave Roussy; Susanne Osanto, MD, PhD, Leiden University Medical Center
Published: Monday, Feb 29, 2016


There are different approaches for overcoming resistance in metastatic renal cell carcinoma (mRCC), states Bernard Escudier, MD. One approach is to target some of the cytokines; another is to target fibroblast growth factor (FGF). Lenvatinib, which inhibits FGF and VEGF, has been tested to try to overcome resistance in mRCC.

In a three-arm phase II study, lenvatinib in combination with everolimus improved progression-free survival by more than 7 months when compared with lenvatinib alone. Lenvatinib has a broad range of targets, says Susanne Osanto, MD. Phase III data are needed to confirm the efficacy in combination with everolimus. However, there tends to be a need to dose-reduce and/or interrupt treatment due to the toxicities with lenvatinib, notes Escudier.
Slider Left
Slider Right


There are different approaches for overcoming resistance in metastatic renal cell carcinoma (mRCC), states Bernard Escudier, MD. One approach is to target some of the cytokines; another is to target fibroblast growth factor (FGF). Lenvatinib, which inhibits FGF and VEGF, has been tested to try to overcome resistance in mRCC.

In a three-arm phase II study, lenvatinib in combination with everolimus improved progression-free survival by more than 7 months when compared with lenvatinib alone. Lenvatinib has a broad range of targets, says Susanne Osanto, MD. Phase III data are needed to confirm the efficacy in combination with everolimus. However, there tends to be a need to dose-reduce and/or interrupt treatment due to the toxicities with lenvatinib, notes Escudier.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x